secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0000950170-25-089741
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health completes Optimization Study for ncVNS device; results due later in 2025
--------------------------------------------------------------------------------

- All study visits completed for patent-pending non-invasive cervical vagus nerve stimulation device.
- Initial findings reinforce importance of personalization for therapeutic efficacy; detailed results expected later this year.
- Earlier findings presented at Bioelectronic Medicine Summit on March 4, 2025.
- CEO Jennifer Ernst says breakthroughs increase confidence in novel bioelectronic approach.
- Global VNS market forecast at $21.3B by 2030; peripheral nerve stimulation segment growing at 35% CAGR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025089741/0000950170-25-089741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025089741/tivc-20250625.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-089741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer